Sorbonne Université, INSERM, CNRS, Institut de la Vision, F-75012 Paris, France.
Faculté de Médecine, Université de Lille, F-59000 Lille, France.
Int J Mol Sci. 2022 Jun 13;23(12):6590. doi: 10.3390/ijms23126590.
Inherited retinal diseases (IRD) are a group of heterogeneous disorders, most of which lead to blindness with limited therapeutic options. Pathogenic variants in RBP4, coding for a major blood carrier of retinol, retinol-binding protein 4, are responsible for a peculiar form of IRD. The aim of this study was to investigate if retinal function of an RBP4-related IRD patient can be improved by retinol administration. Our patient presented a peculiar white-dot retinopathy, reminiscent of vitamin A deficient retinopathy. Using a customized next generation sequencing (NGS) IRD panel we discovered a novel loss-of-function homozygous pathogenic variant in RBP4: c.255G >A, p.(Trp85*). Western blotting revealed the absence of RBP4 protein in the patient’s serum. Blood retinol levels were undetectable. The patient was put on a high-dose oral retinol regimen (50,000 UI twice a week). Subjective symptoms and retinal function markedly and sustainably improved at 5-months and 1-year follow-up. Here we show that this novel IRD case can be treated by oral retinol administration.
遗传性视网膜疾病(IRD)是一组异质性疾病,其中大多数会导致失明,且治疗选择有限。视黄醇结合蛋白 4(编码视黄醇的主要血液载体)的致病性变异可引起一种特殊形式的 IRD。本研究旨在探讨视黄醇给药是否可以改善 RBP4 相关 IRD 患者的视网膜功能。我们的患者表现出一种特殊的白点性视网膜病变,类似于维生素 A 缺乏性视网膜病变。使用定制的下一代测序(NGS)IRD 面板,我们在 RBP4 中发现了一个新的纯合失功能致病性变异:c.255G > A,p.(Trp85*)。Western blot 显示患者血清中缺乏 RBP4 蛋白。血液视黄醇水平无法检测到。患者接受了高剂量口服视黄醇治疗方案(每周两次,每次 50,000 UI)。在 5 个月和 1 年的随访中,患者的主观症状和视网膜功能显著且持续改善。本研究表明,这种新型 IRD 病例可以通过口服视黄醇治疗。